Amelioration of sexual adverse effects in the early breast cancer patient

Journal of Cancer Survivorship

Volumn 4, Issue 3, 2010, Pages 247-255

  Melisko, Michelle E ^a   Goldman, Mindy ^a   Rugo, Hope S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Estrogen; Libido; Sexual dysfunction; Testosterone; Vaginal dryness

Indexed keywords

BREAST TUMOR; FEMALE; HUMAN; QUALITY OF LIFE; REVIEW; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SURVIVOR;

BREAST NEOPLASMS; FEMALE; HUMANS; QUALITY OF LIFE; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SURVIVORS;

EID: 78649632793     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-010-0130-1     Document Type: Review

References (54)

1. Barni S, Mondin R. Sexual dysfunction in treated breast cancer patients. Ann Oncol. 1997; 8: 149-53.
2. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol. 1998; 16: 501-14.
3. Speer JJ, Hillenberg B, Sugrue DP, et al. Study of sexual functioning determinants in breast cancer survivors. Breast J. 2005; 11: 440-7.
4. Burwell SR, Case LD, Kaelin C, Avis NE. Sexual problems in younger women after breast cancer surgery. J Clin Oncol. 2006; 24: 2815-21.
5. Ganz PA, Greendale GA, Petersen L, Kahn B, Bower JE. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol. 2003; 21: 4184-93.
6. Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst. 2002; 94: 39-49.
7. Broeckel JA, Thors CL, Jacobsen PB, Small M, Cox CE. Sexual functioning in long-term breast cancer survivors treated with adjuvant chemotherapy. Breast Cancer Res Treat. 2002; 75: 241-8.
8. Yoon J, Malin JL, Tisnado DM, et al. Symptom management after breast cancer treatment: is it influenced by patient characteristics? Breast Cancer Res Treat 2007.
9. Young-McCaughan S. Sexual functioning in women with breast cancer after treatment with adjuvant therapy. Cancer Nurs. 1996; 19: 308-19.
10. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001; 62 Suppl 3: 10-21.
11. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000; 356: 2059-63.
12. Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol. 2006; 24: 1409-14.
13. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009; 70: 1688-97.
14. Mathias C, Cardeal Mendes CM, Ponde de Sena E, et al. An open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer. Ann Oncol. 2006; 17: 1792-6.
15. Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs. 2004; 15: 753-60.
16. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol. 2004; 22: 4261-71.
17. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006; 100: 273-84.
18. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 2006; 24: 910-7.
19. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Jama. 2006; 295: 2742-51.
20. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause (New York, NY). 2000; 7: 156-61.
21. Simunic V, Banovic I, Ciglar S, Jeren L, Pavicic Baldani D, Sprem M. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet. 2003; 82: 187-97.
22. Barentsen R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol. 1997; 71: 73-80.
23. Sarkar NN. Low-dose intravaginal estradiol delivery using a Silastic vaginal ring for estrogen replacement therapy in postmenopausal women: a review. Eur J Contracept Reprod Health Care. 2003; 8: 217-24.
24. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005; 8: 83-92.
25. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006; 17: 584-7.
26. Kloosterboer HJ. Tissue-selective effects of tibolone on the breast. Maturitas. 2004; 49: S5-S15.
27. Gompel A, Siromachkova M, Lombet A, Kloosterboer HJ, Rostene W. Tibolone actions on normal and breast cancer cells. Eur J Cancer. 2000; 36 Suppl 4: S76-7.
28. Morris EP, Wilson PO, Robinson J, Rymer JM. Long term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynaecol. 1999; 106: 954-9.
29. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008; 359: 697-708.
30. Tibolone study in breast cancer patients to close ahead of schedule. 2007 [cited 2007 October 6]; Press Release]. Available from:.
31. Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 2009; 10: 135-46.
32. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol. 1997; 15: 969-73.
33. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996; 23: 259-63.
34. Nachtigall LE. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril. 1994; 61: 178-80.
35. Rowland JH, Meyerowitz BE, Crespi CM, et al. Addressing intimacy and partner communication after breast cancer: a randomized controlled group intervention. Breast Cancer Res Treat. 2009; 118: 99-111.
36. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J. 2000; 14: 1725-30.
37. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst. 1996; 88: 291-6.
38. Yu H, Shu XO, Shi R, et al. Plasma sex steroid hormones and breast cancer risk in Chinese women. Int J Cancer. 2003; 105: 92-7.
39. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998; 90: 1292-9.
40. Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JM, et al. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am J Epidemiol. 1997; 145: 1030-8.
41. Somboonporn W, Davis SR. Postmenopausal testosterone therapy and breast cancer risk. Maturitas. 2004; 49: 267-75.
42. Rock CL, Flatt SW, Laughlin GA, et al. Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomark Prev. 2008; 17: 614-20.
43. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005; 90: 3847-53.
44. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2000; 85: 645-51.
45. Burger HG. Androgen production in women. Fertil Steril. 2002; 77 Suppl 4: S3-5.
46. Arlt W. Androgen therapy in women. Eur J Endocrinol. 2006; 154: 1-11.
47. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med. 2005; 165: 1582-9.
48. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol. 2005; 105: 944-52.
49. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000; 343: 682-8.
50. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008; 359: 2005-17.
51. Krychman ML, Stelling CJ, Carter J, Hudis CA. A case series of androgen use in breast cancer survivors with sexual dysfunction. J Sex Med 2007.
52. Barton DL, Wender DB, Sloan JA, et al. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. J Natl Cancer Inst. 2007; 99: 672-9.
53. http://clinicaltrials. gov/ct2/show/study/NCT00698035?view=results. Vaginal testosterone cream vs ESTRING for vaginal dryness or decreased libido in early stage breast cancer patients (E-String). 2009 February 23, 2009 [cited; Available from:.
54. http://clinicaltrials. gov/ct2/show/NCT00343382?term=pilocarpine& rank=4. Pilocarpine in treating vaginal dryness in patients with breast cancer. 2009 May 21, 2009 [cited; Available from:.